To the criticism that the rate of reimbursement extensions for anticancer drugs have been falling, the Health Insurance Review and Assessment Service had pointed to the increased number of high-priced drugs that are being covered with the RSA system.

HIRA had explained that the increased number of drugs covered through the RSA system since 2017, such as immuno-oncology drugs and targeted drugs, have increased the need to consider the cost-effectiveness and fiscal impact of drugs that require reimbursement extensions.

Ahead of the NA audit scheduled for the 15th, HIRA submitted a ‘Report on the results of the requested corrections and processes from the 2020 NA audit’ that contains the